Table 1.

Patient characteristics of the 64 AML study participants.

		With GS	Without GS
Number of patients		9	55
Age (median)		59 (33–82)	65 (21–86)
White blood cells (μL)		14750 (2100–91,800)	4800 (700–205,800)
Blasts in peripheral blood (%)		46.0 (0–99)	18.0 (0–99)
Blasts in bone marrow (%)		56.3 (32–85.2)	49.0 (13–99)
Karyotype risk (%)	Favorable	1 (11.1)	8 (14.6)
	Intermediate	5 (56.6)	25 (45.4)
	Adverse	3 (33.3)	21 (38.1)
	N.A.	−	1 (1.8)
Chemotherapy	+	9 (100.0)	43 (78.1)
	−	0 (0.0)	8 (14.6)
	Unknown	−	4 (7.3)
Response	Complete Remission (CR)	7 (77.8)	20 (46.5)
	Non-CR	2 (22.2)	19 (44.1)
	Unknown	−	4 (9.3)